Schering-Plough Drugs Get Expanded EU OK
Posted on: Monday, 25 June 2007, 12:04 CDT
Schering-Plough said Monday the European Commission approved duo therapy of Pegintron and Rebetol for treating hepatitis C and HIV co-infections.
The drugs were previously approved for treating hepatitis C alone.
Effective treatment of HCV is critically important for people coinfected with HIV, as liver disease caused by chronic HCV infection is now a leading cause of morbidity and mortality among these patients, Josep Mallolas of the Hospital Clinic Universitari de Barcelona in Spain, a lead author of one of the studies supporting the approval, said in a statement issued by Schering-Plough.
The company estimates 40 percent of the approximately 2.5 million people infected with HIV in Europe are also infected with HCV.
Source: United Press International
Related Articles
- Why Are Some Veterans Who Are Coinfected With Hepatitis C and HIV More Likely to Be Treated for HCV Than Others?
- Cytheris Wins E1.5 Million OSEO Grant for HCV Program
- Cytheris Receives EUR 1.5 Million ($2.3 Million) From OSEO for HCV Clinical Development Program
- Peregrine Announces Addition of The Johns Hopkins Hospital As Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
- Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
- Peregrine Pharmaceuticals Initiates Bavituximab Clinical Trial in HCV Patients Co-Infected With HIV
- PEGINTRON(TM) and REBETOL(R) Combination Therapy Approved in European Union for Treating Hepatitis C in Patients Coinfected With HIV
- European Union's CHMP Issues Positive Opinion on PEGINTRON(Tm) and REBETOL(R) Combination Therapy for Hepatitis C in Patients Coinfected With HIV
- Whites fare poorly with HIV and hepatitis C
- FDA Approves Pegasys and Copegus As Only Hepatitis C Treatment for HIV Patients
 |
 |
User Comments (0)
RSS Feeds